PedSjD n=19 | Diagnostic adSjD n=32 | PedSjD versus diagnostic adSjD P value | Trial adSjD n=42 | PedSjD versus trial adSjD P value | |
Focus score* | 2.6 (1.3–3.4) | 1.1 (0.3–1.8)† | 0.003 | 1.82 (1.2–4.67) | 0.79 |
Focus score ≥1, n (%) | 16 (84.2) | 21 (65.6) | 0.20 | 36 (85.7) | 1.00 |
CD45+ cells* (% of parenchyma) | 20.4 (9.3–35) | 10.35 (2.26–24.01) | 0.041 | 16.3 (4.9–28.9) | 0.46 |
LELs/mm2* | 0.00 (0.00–0.29) | 0.14 (0.00–0.26) | 0.94 | 0.08 (0.00–0.35) | 0.79 |
Presence of LELs, n (%) | 9 (48) | 18 (56) | 0.54 | 23 (56) | 0.53 |
LEL severity (1–3)* | 2 (1–3) | 2 (1–3) | 0.87 | 1 (1–2) | 0.27 |
CD21+ FDC networks/mm2* | 0.21 (0.06–0.79)† | 0.00 (0.00–0.35) | 0.029 | 0.21 (0.00–0.46) | 0.28 |
Bcl6+ ectopic GC/mm2* | 0.14 (0.04–0.33) | 0.00 (0.00–0.12) | 0.002 | 0.00 (0.00–0.24) | 0.018 |
CD3+ cells/mm2* | 1384 (841–1883) | 470 (177–1406) | 0.029 | 715 (256–1917) | 0.15 |
CD20+ cells/mm2* | 1679 (428–2811) | 376 (61–1003) | 0.004 | 624 (108–1300) | 0.023 |
CD20/(CD20+CD3) ratio* | 0.51 (0.32–0.58) | 0.39 (0.25–0.48) | 0.013 | 0.40 (0.23–0.50) | 0.023 |
CD3/CD20 segregation, n (%) | 14 (74) | 18 (56) | 0.21 | 24 (57) | 0.22 |
IgA/IgG plasma cell shift, n (%) | 9 (47) | 18 (56) | 0.54 | 24 (57) | 0.48 |
IgM+plasma cells/mm2* | 68 (25–156) | 42 (10–93) | 0.09 | 29 (6–93) | 0.007 |
Significant p values are italicised and bold.
*Data are reported as median (IQR) or n (%).
†Missing data: 0–5.
adSjD, adult-onset Sjögren’s disease; FDC, follicular dendritic cell; GC, germinal centre; IgA, immunoglobulin A; LEL, lymphoepithelial lesion; PedSjD, paediatric-onset Sjögren’s disease.